- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03169101
Cognition and Smoking Relapse (HCS) (HCS)
Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence Among HIV-infected Smokers
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Males and females 18 years of age or older who self-report smoking at least 5 cigarettes (menthol and non-menthol) per day, on average.
HIV status
- HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 12 months prior to enrollment.
- HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test.
- Able to use transdermal nicotine (TN) safely, based on a medical evaluation.
- Residing in the geographic area for at least 4 months.
- Women of childbearing potential (based on medical history) must consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are in the study and using transdermal nicotine.
- Able to communicate fluently in English.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent/HIPAA form.
Exclusion Criteria:
Smoking Behavior
- Current enrollment or plans to enroll in another smoking cessation program in the next 4 months.
- Regular (daily) use of electronic cigarettes, chewing tobacco, snuff, snus, cigars, cigarillos, or pipes.
- Current use or plans to use nicotine substitutes (gum, patch, lozenge, e-cigarette) or smoking cessation treatments in the next 4 months.
Alcohol/Drug Exclusion Criteria
- Current untreated and unstable diagnosis of substance dependence (eligible if past use and if receiving treatment and stable for at least 30 days). Current untreated and unstable diagnosis of substance abuse requires Study Physician approval.
- A positive urine drug screen for cocaine, amphetamines, methamphetamines, Phencyclidine (PCP), barbiturates, ecstasy (MDMA) at Intake (see Measures and Table 1 for details). At Lab 1 and Lab 2, positive urine drug screens will be reviewed on a case-by-case basis. The PI will determine if the participant will be excluded or allowed to reschedule the visit, at which time they must provide a negative drug screen to continue with the study.
Medication Exclusion Criteria
Current use or recent discontinuation (within last 14 days) of the following medications:
Other smoking cessation medications (e.g. Zyban, Wellbutrin, Wellbutrin sustained release (SR), Chantix)
a. Note: Once participants are found eligible for the study, they are instructed to only use the NRT provided to them by the study staff. If a subject reports using a non-study smoking cessation medication (including other forms of NRT), the study physician and PI will evaluate the situation and determine if it is safe for the subject to continue participation.
- Anti-psychotic medications (if used to treat psychotic symptoms. Other uses may be eligible pending physician approval).
- Daily use of opiate-containing medications for chronic pain (Duragesic/fentanyl patches, Percocet, Oxycontin). Smokers who report taking opiate-containing medications on an "as-needed" basis will be instructed to refrain from use until their study participation is over and that they will be tested to ensure they have complied with this requirement.
- Asthma medications/corticosteroids (requires physician approval)
- Anti-depressants (require physician approval)
Medical Exclusion Criteria
- Females who self-report current pregnancy, planning a pregnancy during the study, or currently breastfeeding/lactating.
- Current diagnosis of unstable and untreated major depression, as determined by self-report & Mini International Neuropsychiatric Interview (MINI) (eligible if stable for at least 30 days).
- Current or past diagnosis of bipolar disorder or psychotic disorder, as determined by self-report or MINI.
- History of heart disease, stroke or MI, unstable angina, or tachycardia (if stable, requires Study Physician approval).
Uncontrolled hypertension (systolic blood pressure (SBP) greater than 160 or diastolic blood pressure (DBP) greater than 100) present at Intake.
a. Note: If a participant presents with blood pressure greater than 160/100 at sessions occurring on Week 3 (Pre-Quit) or at any other point during the treatment period, they will not be provided with/able to continue on TN unless the study physician grants approval.
- Previous allergic reaction to TN.
- History of diabetes (requires Study Physician approval)
- History of seizures (requires Study Physician approval)
- History of stomach ulcers (requires Study Physician approval)
Suicide History Exclusion Criteria
1. Suicide risk as indicated by at least one of the following on the Columbia Suicide Severity Rating Scale (the PI &/or study psychologist will be consulted to assess safety and determine eligibility in cases close to the eligibility cutoffs):
- Current suicidal ideation (within 30 days of enrollment)
- Two or more lifetime suicide attempts
- Any suicide attempt within 2 years of enrollment
General Exclusion Criteria
- Any medical condition or concomitant medication that could compromise subject safety or treatment, as determined by the Principal Investigator and/or Study Physician.
- Color blindness.
- Any impairment (physical and/or neurological) including visual or other impairment preventing cognitive task performance.
- Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
---|---|
HIV+
HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
|
All participants will receive nicotine patches to aid in quitting smoking.
TN is available over the counter and is very well tolerated.
Participants will use "the patch" in a tapering fashion as recommended by the manufacturer.
Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks.
Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.
Ostatní jména:
Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
|
HIV-
HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
|
All participants will receive nicotine patches to aid in quitting smoking.
TN is available over the counter and is very well tolerated.
Participants will use "the patch" in a tapering fashion as recommended by the manufacturer.
Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks.
Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.
Ostatní jména:
Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Cognitive function
Časové okno: Lab session 1 (week 1), lab session 2 (week 2), End of treatment (week 12)
|
Cognitive function will be assessed at the Lab session 1 and lab session 2 visits as well as End of Treatment.
Participants will complete measures of executive function, verbal learning and memory and response inhibition.
The primary outcome is the change in cognitive function lab session 1, lab session 2, and End of Treatment measured by a composite score (calculated by averaging individual z-scores).
|
Lab session 1 (week 1), lab session 2 (week 2), End of treatment (week 12)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
7-day point prevalence abstinence
Časové okno: End of Treatment (week 12)
|
Smoking abstinence (primary outcome) will be assessed and biochemically verified at the End of Treatment Visit (week 12).
The primary smoking outcome variable will be 7-day point prevalence abstinence (no smoking, not even a puff, for at least 7 days prior to the assessment) biochemically verified by carbon monoxide < 5 ppm.
|
End of Treatment (week 12)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Rebecca L Ashare, Ph.D., University of Pennsylvania
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 824860
- R01DA042682 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Nicotine patch
-
Baylor College of MedicineNábor
-
The University of Texas Health Science Center at...Patch Rx TechnologiesDokončenoCystická fibróza | Adherence, lékySpojené státy
-
Xiros LtdZatím nenabírámeRoztržení manžety rotátoru | Zranění rotátorové manžety | Slzy rotátorové manžety | Rotátorová manžeta slzy na rameni
-
Verily Life Sciences LLCUkončeno
-
Metronom HealthMedical University of GrazStaženoDiabetes Mellitus
-
Rockefeller UniversityWashington University School of Medicine; Tel Aviv UniversityDokončenoAlergická kontaktní dermatitidaSpojené státy